Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

QUEST MEDICAL SET TO PENETRATE SECONDARY MEDICATION I.V. MARKET VIA an attachment that will convert a standard disposable syringe into a secondary intravenous fluid container without the need for a plunger. The concept will allow hospitals to replace disposable mini-bags and mini-bottles currently used in secondary medication delivery with standard hospital syringes, resulting in both labor and materials savings, Quest maintains. An average syringe used in secondary medication intravenous treatments costs approximately 25›, as compared with average costs of $1.25 per mini-bag and 90› per mini-bottle, a Quest official said. The new Quest set also will compete with automatic plunger equipment in the nondisposable area. Used with secondary medication syringe containers, that equipment costs between $400 and $500 each, the spokesman said. The company, currently conducting clinical trials with prototype sets, hopes to be ready for manufacturing and marketing in "the latter half of 1984," the spokesman said. Quest has filed an application with FDA for 510(k) clearance of the system, the spokesman said. The as-yet-unnamed product consists of the syringe attachment, which enables fluids to be drawn from the syringe, and a length of plastic tubing to attach to the primary IV line. The product will fit various standard syringe sizes, according to the spokesman. Quest describes the market potential for its attachment product as "significant," based on estimates of between 150 and 200 million mini-bags and mini-bottles sold per year to hospitals. The company plans to introduce its system nationally through its 12-person direct sales force and an additional 25-to-30-agent network. Dallas, Texas-based Quest reported sales of $4.8 mil. for calendar year 1983. Principally a mfr. of custom intravenous sets, Retracto surgical tape, and endotracheal feeding tubes, last fall Quest introduced its Model 1001 Intelligent Infusor intravenous system. According to Quest, the device combines the volumetric measuring advantages of I.V. infusion pumps with the natural pressure system of an I.V. controller. Approximately 270 Intelligent Infusor units have been sold thus far, the spokesman said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts